These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

463 related items for PubMed ID: 20453192

  • 1. Altering the pathophysiology of atherosclerosis: the multidimensional role of statins.
    Clearfield MB.
    J Am Osteopath Assoc; 2010 Apr; 110(4 Suppl 4):S2-6. PubMed ID: 20453192
    [Abstract] [Full Text] [Related]

  • 2. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S, Ridker PM.
    Am J Cardiol; 2006 Jan 16; 97(2A):33A-41A. PubMed ID: 16442935
    [Abstract] [Full Text] [Related]

  • 3. A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease.
    Packard C.
    Atheroscler Suppl; 2006 Apr 16; 7(1):21-9. PubMed ID: 16504600
    [Abstract] [Full Text] [Related]

  • 4. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G, Maggioni AP.
    Adv Ther; 2009 May 16; 26(5):469-87. PubMed ID: 19444394
    [Abstract] [Full Text] [Related]

  • 5. Intensive statin therapy for Indians: Part-I. Benefits.
    Enas EA, Pazhoor HC, Kuruvila A, Vijayaraghavan K.
    Indian Heart J; 2011 May 16; 63(3):211-27. PubMed ID: 22734339
    [Abstract] [Full Text] [Related]

  • 6. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
    Ridker PM, MacFadyen JG, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Study Group.
    Circ Cardiovasc Qual Outcomes; 2009 Nov 16; 2(6):616-23. PubMed ID: 20031900
    [Abstract] [Full Text] [Related]

  • 7. Statins and LDL-cholesterol lowering: an overview.
    Stroes E.
    Curr Med Res Opin; 2005 Nov 16; 21 Suppl 6():S9-16. PubMed ID: 16138936
    [Abstract] [Full Text] [Related]

  • 8. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
    Stewart RA.
    Future Cardiol; 2009 May 16; 5(3):231-6. PubMed ID: 19656039
    [Abstract] [Full Text] [Related]

  • 9. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
    Robinson JG.
    Am J Cardiol; 2008 Apr 01; 101(7):1009-15. PubMed ID: 18359323
    [Abstract] [Full Text] [Related]

  • 10. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature.
    Patrick L, Uzick M.
    Altern Med Rev; 2001 Jun 01; 6(3):248-71. PubMed ID: 11410071
    [Abstract] [Full Text] [Related]

  • 11. Optimal medical management of peripheral arterial disease.
    Rice TW, Lumsden AB.
    Vasc Endovascular Surg; 2006 Jun 01; 40(4):312-27. PubMed ID: 16959725
    [Abstract] [Full Text] [Related]

  • 12. [JUPITER can yield paradigmatic shift in the prevention of cardiovascular disease. Focus on inflammation as a risk factor].
    Olsson AG.
    Lakartidningen; 2006 Jun 01; 106(21-22):1471-5. PubMed ID: 19579435
    [No Abstract] [Full Text] [Related]

  • 13. Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study.
    Fonseca FA, Izar MC.
    Expert Rev Cardiovasc Ther; 2009 Sep 01; 7(9):1041-56. PubMed ID: 19764857
    [Abstract] [Full Text] [Related]

  • 14. [Inflammation and C-reactive protein in cardiovascular disease].
    Munk PS, Larsen AI.
    Tidsskr Nor Laegeforen; 2009 Jun 11; 129(12):1221-4. PubMed ID: 19521445
    [Abstract] [Full Text] [Related]

  • 15. Emerging non-statin LDL-lowering therapies for dyslipidemia and atherosclerosis.
    Shah PK.
    Rev Cardiovasc Med; 2003 Jun 11; 4(3):136-41. PubMed ID: 12949442
    [Abstract] [Full Text] [Related]

  • 16. Primary prevention trials: lessons learned about treating high-risk patients with dyslipidemia without known cardiovascular disease.
    Ferdinand KC.
    Curr Med Res Opin; 2005 Jul 11; 21(7):1091-7. PubMed ID: 16004678
    [Abstract] [Full Text] [Related]

  • 17. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study.
    Michos ED, Blumenthal RS.
    J Am Coll Cardiol; 2009 Mar 17; 53(11):931-5. PubMed ID: 19281922
    [Abstract] [Full Text] [Related]

  • 18. The JUPITER trial: How will it change clinical practice?
    Watson KE.
    Rev Cardiovasc Med; 2009 Mar 17; 10(2):91-6. PubMed ID: 19593321
    [Abstract] [Full Text] [Related]

  • 19. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein.
    Ridker PM, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Khurmi NS, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Trial Study Group.
    Am J Cardiol; 2007 Dec 01; 100(11):1659-64. PubMed ID: 18036365
    [Abstract] [Full Text] [Related]

  • 20. Statins and stroke prevention.
    Paciaroni M, Hennerici M, Agnelli G, Bogousslavsky J.
    Cerebrovasc Dis; 2007 Dec 01; 24(2-3):170-82. PubMed ID: 17596685
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.